

# SUMMARY OF PRODUCT CHARACTERISTICS

## 1 NAME OF THE MEDICINAL PRODUCT

Fexofenadine Hydrochloride 180 mg Film-coated tablets  
Algexia MAX 180mg film-coated Tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 180 mg of fexofenadine hydrochloride.  
Excipient(s) with known effect: Each tablet contains 228.630 mg of lactose monohydrate.  
For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Film-coated Tablet  
Peach coloured capsule shaped film-coated tablets of 17.10 mm x 7.60 mm x 5.30 mm, debossed as '180' on one side and 'FX' on other side.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic indications

The product is indicated in adults and children 12 years and older for the relief of symptoms associated with chronic idiopathic urticaria.

### 4.2 Posology and method of administration

#### Posology

#### *Adults*

The recommended dose of fexofenadine hydrochloride for adults is 180 mg once daily taken before a meal.  
Fexofenadine hydrochloride is a pharmacologically active metabolite of terfenadine.

#### *Paediatric population*

##### *Children aged 12 years and over*

The recommended dose of fexofenadine hydrochloride for children aged 12 years and over is 180 mg one daily taken before a meal.

##### *Children under 12 years of age*

The efficacy and safety of the product has not been studied in children under 12.

#### *Special populations*

Studies in special risk groups (older people, renally or hepatically impaired patients) indicate that it is not necessary to adjust the dose of fexofenadine hydrochloride in these patients.

#### **Method of administration**

For oral use

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

### **4.4 Special warnings and precautions for use:**

There is only limited data in older people and renally or hepatically impaired patients. Fexofenadine hydrochloride should only be administered in these special groups on the advice of a doctor.

Patients with a history of or ongoing cardiovascular disease should be warned that, antihistamines as a medicine class, have been associated with the adverse reactions, tachycardia and palpitations (see section 4.8) and should use fexofenadine hydrochloride only on the advice of their doctor.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

### **4.5 Interaction with other medicinal products and other forms of interaction**

Fexofenadine hydrochloride does not undergo hepatic biotransformation and therefore will not interact with other medicinal products through hepatic mechanisms.

Fexofenadine hydrochloride is a P-glycoprotein (P-gp) and organic-anion-transporting polypeptide (OATP) substrate. Concomitant use of fexofenadine with P-gp inhibitors or inducers can affect the exposure to fexofenadine hydrochloride. Coadministration of fexofenadine hydrochloride with P-gp inhibitors erythromycin or ketoconazole has been found to result in a 2-3 times increase in the level of fexofenadine hydrochloride in plasma. The changes were not accompanied by any effects on the QT interval and were not associated with any increase in adverse reactions compared to the medicinal products given singly.

A clinical drug-drug interaction study showed that co-administration of apalutamide (a weak inducer of P-gp) and a single oral dose of 30 mg fexofenadine hydrochloride resulted in a 30 % decrease in AUC of fexofenadine.

No interaction between fexofenadine hydrochloride and omeprazole was observed. However, the administration of an antacid containing aluminium and magnesium hydroxide gels 15 minutes prior to fexofenadine hydrochloride caused a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. It is advisable to leave 2 hours between administration of fexofenadine hydrochloride and aluminium and magnesium hydroxide containing antacids.

## **4.6 Fertility, pregnancy and lactation**

### **Pregnancy**

There are no adequate data from the use of fexofenadine hydrochloride in pregnant women.

Limited animal studies do not indicate direct or indirect harmful effects with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Fexofenadine hydrochloride should not be used during pregnancy unless on the advice of a doctor.

### **Breast-feeding**

There are no data on the content of human milk after administering fexofenadine hydrochloride. However, when terfenadine was administered to nursing mothers' fexofenadine hydrochloride was found to cross into human breast milk. Therefore, fexofenadine hydrochloride is not recommended for mothers breast-feeding their babies. Breastfeeding women should only use fexofenadine hydrochloride if advised to do so by a doctor.

### **Fertility**

No human data on the effect of fexofenadine hydrochloride on fertility are available. In mice, there was no effect on fertility with fexofenadine hydrochloride treatment (see section 5.3).

## **4.7 Effects on ability to drive and use machines**

On the basis of the pharmacodynamic profile and reported adverse reactions it is unlikely that fexofenadine hydrochloride tablets will produce an effect on the ability to drive or use machines.

In objective tests, fexofenadine hydrochloride has been shown to have no significant effects on central nervous system function. This means that patients may drive or perform tasks that require concentration. However, in order to identify sensitive people who have an unusual reaction to medicinal products, it is advisable to check the individual response before driving or performing complicated tasks.

## **4.8 Undesirable effects**

The following frequency rating has been used, when applicable:

Very common  $\geq 1/10$ ; Common  $\geq 1/100$  and  $< 1/10$ ; Uncommon  $\geq 1/1,000$  and  $< 1/100$ ; Rare  $\geq 1/10,000$  and  $< 1/1,000$ ; Very rare  $< 1/10,000$  and not known (frequency cannot be estimated from the available data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

In adults, the following undesirable effects have been reported in clinical trials, with an incidence similar to that observed with placebo:

*Nervous system disorders*

Common: headache, drowsiness, dizziness

*Eye disorders*

Not known: Vision blurred

*Gastrointestinal disorders*

Common: nausea

*General disorders and administration site conditions*

Uncommon: fatigue

In adults, the following undesirable effects have been reported in post-marketing surveillance. The frequency with which they occur is not known (can not be estimated from available data):

*Immune system disorders*

hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, flushing and systemic anaphylaxis

*Psychiatric disorders* insomnia, nervousness, sleep disorders or nightmares/excessive dreaming (paroniria)

*Cardiac disorders*

tachycardia, palpitations

*Gastrointestinal disorders* diarrhoea

*Skin and subcutaneous tissue disorders*

rash, urticaria, pruritus

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

## 4.9 Overdose

Dizziness, drowsiness, fatigue and dry mouth have been reported with overdose of fexofenadine hydrochloride. Single doses up to 800 mg and doses up to 690 mg twice daily for 1 month or 240 mg once daily for 1 year have been administered to healthy subjects without the development of clinically significant adverse reactions as compared with placebo. The maximum tolerated dose of fexofenadine hydrochloride has not been established.

Standard measures should be considered to remove any unabsorbed medicinal product. Symptomatic and supportive treatment is recommended. Haemodialysis does not effectively remove fexofenadine hydrochloride from blood.

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antihistamines for systemic use, ATC code: R06A X26.

#### Mechanism of action

Fexofenadine hydrochloride is a non-sedating H<sub>1</sub> antihistamine. Fexofenadine hydrochloride is a pharmacologically active metabolite of terfenadine.

#### Clinical efficacy and safety

Human histamine wheal and flare studies following single and twice daily doses of fexofenadine hydrochloride demonstrate that the medicinal product exhibits an antihistaminic effect beginning within one hour, achieving maximum at 6 hours and lasting 24 hours. There was no evidence of tolerance to these effects after 28 days of dosing. A positive dose-response relationship between doses of 10 mg to 130 mg taken orally was found to exist. In this model of antihistaminic activity, it was found that doses of at least 130 mg were required to achieve a consistent effect that was maintained over a 24 hour period. Maximum inhibition in skin wheal and flare areas were greater than 80%.

No significant differences in QT<sub>c</sub> intervals were observed in seasonal allergic rhinitis patients given fexofenadine hydrochloride up to 240 mg twice daily for 2 weeks when compared to placebo. Also, no significant change in QT<sub>c</sub> intervals was observed in healthy subjects given fexofenadine hydrochloride up to 60 mg twice daily for 6 months, 400 mg twice daily for 6.5 days and 240 mg once daily for 1 year, when compared to placebo. Fexofenadine hydrochloride at concentrations 32 times greater than the therapeutic concentration in man had no effect on the delayed rectifier K<sup>+</sup> channel cloned from human heart.

Fexofenadine hydrochloride (5-10 mg/kg po) inhibited antigen induced bronchospasm in sensitised guinea pigs and inhibited histamine release at supratherapeutic concentrations (10-100 µM) from peritoneal mast cells.

### 5.2 Pharmacokinetic properties

#### Absorption

Fexofenadine hydrochloride is rapidly absorbed into the body following oral administration, with  $T_{max}$  occurring at approximately 1-3 hours post dose. The mean  $C_{max}$  value was approximately 494 ng/ml following the administration of a 180 mg dose once daily.

### **Distribution**

Fexofenadine is 60-70% plasma protein bound.

### **Biotransformation and elimination**

Fexofenadine hydrochloride undergoes negligible metabolism (hepatic or non-hepatic), as it was the only major compound identified in urine and faeces of animals and man. The plasma concentration profiles of fexofenadine hydrochloride follow a bi-exponential decline with a terminal elimination half-life ranging from 11 to 15 hours after multiple dosing. The single and multiple dose pharmacokinetics of fexofenadine hydrochloride are linear for oral doses up to 120 mg BID. A dose of 240 mg BID produced slightly greater than proportional increase (8.8%) in steady state area under the curve, indicating that fexofenadine hydrochloride pharmacokinetics are practically linear at these doses between 40 mg and 240 mg taken daily. The major route of elimination is believed to be via biliary excretion while up to 10% of ingested dose is excreted unchanged through the urine.

## **5.3 Preclinical safety data**

Dogs tolerated 450 mg/kg administered twice daily for 6 months and showed no toxicity other than occasional emesis. Also, in single dose dog and rodent studies, no treatment-related gross findings were observed following necropsy.

Radiolabelled fexofenadine hydrochloride in tissue distribution studies of the rat indicated that fexofenadine did not cross the blood brain barrier.

Fexofenadine hydrochloride was found to be non-mutagenic in various *in vitro* and *in vivo* mutagenicity tests.

The carcinogenic potential of fexofenadine hydrochloride was assessed using terfenadine studies with supporting pharmacokinetic studies showing fexofenadine hydrochloride exposure (via plasma AUC values). No evidence of carcinogenicity was observed in rats and mice given terfenadine (up to 150 mg/kg/day).

In a reproductive toxicity study in mice, fexofenadine hydrochloride did not impair fertility, was not teratogenic and did not impair pre- or postnatal development.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Lactose monohydrate

Low-substituted-Hydroxypropyl Cellulose(E463)

Pregelatinised starch

Colloidal anhydrous silica (E551)

Microcrystalline cellulose (E460)

Croscarmellose sodium (E468)

Magnesium stearate (E572)

Hypromellose

Povidone

Titanium dioxide (E171)

Iron oxide Red (E172)

Iron oxide Yellow (E172)

Macrogol 400

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf life**

3 years

## **6.4 Special precautions for storage**

This medicinal product does not require any special storage condition.

## **6.5 Nature and contents of container**

The product is provided in blisters of Alu-PVC/PVDC or Alu /PVC/PE/ACLAR in pack size of 7, 10, 14, 15, 20, 21, 28 or 30 tablets.

Not all pack sizes may be marketed.

## **6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7      MARKETING AUTHORISATION HOLDER**

Noumed Life Sciences Limited,  
Noumed House  
Shoppenhangers Road  
Maidenhead, Berkshire SL6 2RB, United Kingdom.

**8      MARKETING AUTHORISATION NUMBER(S)**

PL 44041/0239

**9      DATE OF FIRST AUTHORISATION/RENEWAL OF THE  
AUTHORISATION**

23/10/2025

**10     DATE OF REVISION OF THE TEXT**

20/05/2026